Brief: Clinical Laserthermia Systems Gets FDA Clearance For Expanded Labeling
04/09/2025 16:01
Sept 4 (Reuters) - Clinical Laserthermia Systems AB CLSRb.ST: CLINICAL LASERTHERMIA SYSTEMS RECEIVES FDA CLEARANCE FOR EXPANDED LABELING OF THE CLEARPOINT PRISM[®] NEURO LASER THERAPY SYSTEM, DOUBLING THE ADDRESSABLE U.S MARKET FOR NEURO LITT Source text: ID:nWkr848rVY Further company coverage: [CLSRb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Clinical Laserthermia Systems AB
See all newsBrief: Clinical Laserthermia Systems AB Resolves On A Directed Issue
Brief: Clinical Laserthermia Appoints Katarina Lundqvist As Permanent CFO
Brief: CLS Announces Outcome In Rights Issue Of Units
Brief: CLS Agrees On Top-Down Guarantee For Rights Issue
Brief: CLS Conducts Rights Issue Of SEK 39.5 Million